立方制药：收到非奈利酮原料药上市申请受理通知书

Core Viewpoint - The company has received a notice of acceptance for the listing application of Finerenone raw materials from the National Medical Products Administration, indicating progress in the registration review phase for this new drug [1] Group 1: Product Development - Finerenone is a novel mineralocorticoid receptor antagonist intended for adult patients with type 2 diabetes-related chronic kidney disease [1] - As of the announcement date, five companies have registered the raw material with status "A," while the others are marked as "I" [1] Group 2: Market Impact - The acceptance of the application does not have a significant impact on the company's recent performance, but successful approval could enhance the company's raw material product pipeline [1] - The timeline and outcome of the registration approval remain uncertain, which may pose risks for investors [1]